MaaT Pharma
@maatpharma.bsky.social
MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival.
Pinned
MaaT Pharma
@maatpharma.bsky.social
· Nov 5
📰 [PressRelease] – We’re thrilled to announce that our Phase 3 results evaluating Xervyteg® (MaaT013) in acute Graft-versus-Host Disease (#aGvHD) have been selected for oral presentation at ASH Congress 2025.
👉 Read the full press release: www.maatpharma.com/november-3-2...
👉 Read the full press release: www.maatpharma.com/november-3-2...
📰 MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis.
👉 Read the press release: www.maatpharma.com/january-20-2...
👉 Read the press release: www.maatpharma.com/january-20-2...
January 20, 2026 at 5:51 PM
📰 MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis.
👉 Read the press release: www.maatpharma.com/january-20-2...
👉 Read the press release: www.maatpharma.com/january-20-2...
📢 Join MaaT Pharma as a Data Engineer (M/F)!
📩 Interested? Send your resume and a short motivation email to careers@maat-pharma.com to apply now!
🔬 Full job description: www.maatpharma.com/wp-content/u...
#DataEngineer #BigData #Biotech #DataScience #Microbiome #HealthcareInnovation
📩 Interested? Send your resume and a short motivation email to careers@maat-pharma.com to apply now!
🔬 Full job description: www.maatpharma.com/wp-content/u...
#DataEngineer #BigData #Biotech #DataScience #Microbiome #HealthcareInnovation
January 19, 2026 at 11:04 AM
📢 Join MaaT Pharma as a Data Engineer (M/F)!
📩 Interested? Send your resume and a short motivation email to careers@maat-pharma.com to apply now!
🔬 Full job description: www.maatpharma.com/wp-content/u...
#DataEngineer #BigData #Biotech #DataScience #Microbiome #HealthcareInnovation
📩 Interested? Send your resume and a short motivation email to careers@maat-pharma.com to apply now!
🔬 Full job description: www.maatpharma.com/wp-content/u...
#DataEngineer #BigData #Biotech #DataScience #Microbiome #HealthcareInnovation
📢 [EVENT] – Join Guilhaume Deboras, Head of Corporate Development of MaaT Pharma, at the 10th Annual @Microbiome Movement Summit Europe, taking place on January 28-29 in London, UK.
👉 Learn more: microbiome-europe.com
#Microbiome #aGvHD #Oncology #Hematology #Innovation #Xervyteg
👉 Learn more: microbiome-europe.com
#Microbiome #aGvHD #Oncology #Hematology #Innovation #Xervyteg
January 15, 2026 at 3:55 PM
📢 [EVENT] – Join Guilhaume Deboras, Head of Corporate Development of MaaT Pharma, at the 10th Annual @Microbiome Movement Summit Europe, taking place on January 28-29 in London, UK.
👉 Learn more: microbiome-europe.com
#Microbiome #aGvHD #Oncology #Hematology #Innovation #Xervyteg
👉 Learn more: microbiome-europe.com
#Microbiome #aGvHD #Oncology #Hematology #Innovation #Xervyteg
🎥 Prof. Florent Malard, MD, PhD, shares insights on the severity and management challenges of aGvHD, a high unmet medical need, and discusses the emerging role of the gut microbiota and Xervyteg® data.
👉 French interview (English subtitled): www.maatpharma.com/patients-car...
@ash.hematology.org
👉 French interview (English subtitled): www.maatpharma.com/patients-car...
@ash.hematology.org
January 13, 2026 at 4:03 PM
🎥 Prof. Florent Malard, MD, PhD, shares insights on the severity and management challenges of aGvHD, a high unmet medical need, and discusses the emerging role of the gut microbiota and Xervyteg® data.
👉 French interview (English subtitled): www.maatpharma.com/patients-car...
@ash.hematology.org
👉 French interview (English subtitled): www.maatpharma.com/patients-car...
@ash.hematology.org
📰 MaaT Pharma featured in PharmaBoardroom!
Hervé Affagard, CEO and Co-Founder of MaaT Pharma, discusses the Company’s journey, scientific vision and path toward a potential first approval.
👉 Read the full interview here: pharmaboardroom.com/interviews/h...
#aGvHD #Oncology #Hematology #Microbiome
Hervé Affagard, CEO and Co-Founder of MaaT Pharma, discusses the Company’s journey, scientific vision and path toward a potential first approval.
👉 Read the full interview here: pharmaboardroom.com/interviews/h...
#aGvHD #Oncology #Hematology #Microbiome
Hervé Affagard – CEO and Co-Founder, MaaT Pharma
MaaT Pharma is entering a defining moment in its mission to bring microbiotherapies into areas of…
pharmaboardroom.com
January 6, 2026 at 3:11 PM
📰 MaaT Pharma featured in PharmaBoardroom!
Hervé Affagard, CEO and Co-Founder of MaaT Pharma, discusses the Company’s journey, scientific vision and path toward a potential first approval.
👉 Read the full interview here: pharmaboardroom.com/interviews/h...
#aGvHD #Oncology #Hematology #Microbiome
Hervé Affagard, CEO and Co-Founder of MaaT Pharma, discusses the Company’s journey, scientific vision and path toward a potential first approval.
👉 Read the full interview here: pharmaboardroom.com/interviews/h...
#aGvHD #Oncology #Hematology #Microbiome
At #ASH2025, Prof. Florent Malard shared Phase III ARES results with #VJHEMONC, highlighting Xervyteg® (MaaT013) in aGvHD: 62% GI response, 64% ORR and 54% 1-year OS.
👉 Full interview: www.vjhemonc.com/video/xm1_uw...
@ash.hematology.org @vjhemonc.bsky.social
👉 Full interview: www.vjhemonc.com/video/xm1_uw...
@ash.hematology.org @vjhemonc.bsky.social
Results of ARES: allogeneic microbiotherapy for ruxolitinib-refractory GvHD with GI involvement
Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, discusses the Phase III ARES trial (NCT04769895) of MaaT013,...
www.vjhemonc.com
December 19, 2025 at 3:14 PM
At #ASH2025, Prof. Florent Malard shared Phase III ARES results with #VJHEMONC, highlighting Xervyteg® (MaaT013) in aGvHD: 62% GI response, 64% ORR and 54% 1-year OS.
👉 Full interview: www.vjhemonc.com/video/xm1_uw...
@ash.hematology.org @vjhemonc.bsky.social
👉 Full interview: www.vjhemonc.com/video/xm1_uw...
@ash.hematology.org @vjhemonc.bsky.social
🎥 Prof. Mohamad Mohty, MD, PhD, in an exclusive interview with VJ HemOnc at #ASH2025, shared #GvHD advances and Xervyteg® (MaaT013) with a 54% one-year survival rate.
👉 Full interview: www.vjhemonc.com/video/uz21rt...
@ash.hematology.org @vjhemonc.bsky.social
👉 Full interview: www.vjhemonc.com/video/uz21rt...
@ash.hematology.org @vjhemonc.bsky.social
Advances in GvHD management presented at ASH 2025
In this interview, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses key advances and developments in graft-versus-host disease (GvHD)...
www.vjhemonc.com
December 17, 2025 at 12:30 PM
🎥 Prof. Mohamad Mohty, MD, PhD, in an exclusive interview with VJ HemOnc at #ASH2025, shared #GvHD advances and Xervyteg® (MaaT013) with a 54% one-year survival rate.
👉 Full interview: www.vjhemonc.com/video/uz21rt...
@ash.hematology.org @vjhemonc.bsky.social
👉 Full interview: www.vjhemonc.com/video/uz21rt...
@ash.hematology.org @vjhemonc.bsky.social
🎥 During #ASH2025 Annual Meeting, Hervé Affagard, CEO and co-founder of MaaT Pharma, was interviewed by Brad Loncar for BiotechTV.
🙏 Many thanks for this insightful discussion and for spotlighting our work.
👉 Watch the full interview: www.biotechtv.com/post/maat-ph...
@biotechtv.bsky.social
🙏 Many thanks for this insightful discussion and for spotlighting our work.
👉 Watch the full interview: www.biotechtv.com/post/maat-ph...
@biotechtv.bsky.social
ASH 2025: MaaT Pharma's microbiome based treatment for refractory GVHD is in front of EMA right now for a possible 2026 approval - the pivotal data was presented in an oral at ASH this week
Founder and CEO Hervé Affagard walks us through how this treatment works and highlights the ASH presentation and one year survival data the company has accrued. Plus, how compassionate use is going in...
www.biotechtv.com
December 16, 2025 at 11:23 AM
🎥 During #ASH2025 Annual Meeting, Hervé Affagard, CEO and co-founder of MaaT Pharma, was interviewed by Brad Loncar for BiotechTV.
🙏 Many thanks for this insightful discussion and for spotlighting our work.
👉 Watch the full interview: www.biotechtv.com/post/maat-ph...
@biotechtv.bsky.social
🙏 Many thanks for this insightful discussion and for spotlighting our work.
👉 Watch the full interview: www.biotechtv.com/post/maat-ph...
@biotechtv.bsky.social
📰 [Press Release] - Live from ASH 2025: MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival
Read the full press release here: www.maatpharma.com/december-8-2...
#ASH2025 #aGvHD #Cancer
Read the full press release here: www.maatpharma.com/december-8-2...
#ASH2025 #aGvHD #Cancer
December 8, 2025 at 5:12 PM
📰 [Press Release] - Live from ASH 2025: MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival
Read the full press release here: www.maatpharma.com/december-8-2...
#ASH2025 #aGvHD #Cancer
Read the full press release here: www.maatpharma.com/december-8-2...
#ASH2025 #aGvHD #Cancer
📅 Heading to #ASH2025!
Meet MaaT Pharma’s Acting CSO Sheri Simmons & CEO Hervé Affagard in Orlando, Dec 6–9.
We’re also excited for Prof. Florent Malard to present Phase 3 ARES trial results on Xervyteg® (MaaT013) in SR GI-aGvHD patients.
👇 Presentation details below.
Meet MaaT Pharma’s Acting CSO Sheri Simmons & CEO Hervé Affagard in Orlando, Dec 6–9.
We’re also excited for Prof. Florent Malard to present Phase 3 ARES trial results on Xervyteg® (MaaT013) in SR GI-aGvHD patients.
👇 Presentation details below.
December 5, 2025 at 11:13 AM
📅 Heading to #ASH2025!
Meet MaaT Pharma’s Acting CSO Sheri Simmons & CEO Hervé Affagard in Orlando, Dec 6–9.
We’re also excited for Prof. Florent Malard to present Phase 3 ARES trial results on Xervyteg® (MaaT013) in SR GI-aGvHD patients.
👇 Presentation details below.
Meet MaaT Pharma’s Acting CSO Sheri Simmons & CEO Hervé Affagard in Orlando, Dec 6–9.
We’re also excited for Prof. Florent Malard to present Phase 3 ARES trial results on Xervyteg® (MaaT013) in SR GI-aGvHD patients.
👇 Presentation details below.
✨ MaaT Pharma showcases its expertise at the 28th Congress of the French Cytometry Association (AFC - Association Française de cytométrie)!
Chloé Badonnel showcased MaaT Pharma’s CMC expertise, presenting MaaT034’s manufacturing and a new flow cytometry method to assess bacterial activity. 👏
Chloé Badonnel showcased MaaT Pharma’s CMC expertise, presenting MaaT034’s manufacturing and a new flow cytometry method to assess bacterial activity. 👏
December 2, 2025 at 11:13 AM
✨ MaaT Pharma showcases its expertise at the 28th Congress of the French Cytometry Association (AFC - Association Française de cytométrie)!
Chloé Badonnel showcased MaaT Pharma’s CMC expertise, presenting MaaT034’s manufacturing and a new flow cytometry method to assess bacterial activity. 👏
Chloé Badonnel showcased MaaT Pharma’s CMC expertise, presenting MaaT034’s manufacturing and a new flow cytometry method to assess bacterial activity. 👏
📢 #Internship – Join MaaT Pharma as a Data Engineer Intern (M/F)!
📩 Interested? Send your CV and a short motivation email to careers@maat-pharma.com to apply now!
🔬 Full job description: www.maatpharma.com/wp-content/u...
📅 6-month internship – starting early 2026
📍 Lyon, France
#DataEngineering
📩 Interested? Send your CV and a short motivation email to careers@maat-pharma.com to apply now!
🔬 Full job description: www.maatpharma.com/wp-content/u...
📅 6-month internship – starting early 2026
📍 Lyon, France
#DataEngineering
December 1, 2025 at 2:24 PM
📢 #Internship – Join MaaT Pharma as a Data Engineer Intern (M/F)!
📩 Interested? Send your CV and a short motivation email to careers@maat-pharma.com to apply now!
🔬 Full job description: www.maatpharma.com/wp-content/u...
📅 6-month internship – starting early 2026
📍 Lyon, France
#DataEngineering
📩 Interested? Send your CV and a short motivation email to careers@maat-pharma.com to apply now!
🔬 Full job description: www.maatpharma.com/wp-content/u...
📅 6-month internship – starting early 2026
📍 Lyon, France
#DataEngineering
🎥 MaaT Pharma sur #BFMBusiness ! Ce matin, Hervé Affagard, CEO et cofondateur de MaaT Pharma, était l’invité Laure Closier dans la rubrique #FrenchTech de Good Morning Business.
👉 Revoir l’interview ici : www.bfmtv.com/economie/rep...
@bfmbusiness.bsky.social
👉 Revoir l’interview ici : www.bfmtv.com/economie/rep...
@bfmbusiness.bsky.social
PODCAST : French Tech : Maat Pharma, un anticancer issu du microbiote - 28/11
Hervé Affagard, cofondateur et directeur général de Maat Pharma, était l'invité de Laure Closier dans French Tech, ce vendredi 28 novembre. Il a expliqué comment fonctionne son médicament à base de mi...
www.bfmtv.com
November 28, 2025 at 11:52 AM
🎥 MaaT Pharma sur #BFMBusiness ! Ce matin, Hervé Affagard, CEO et cofondateur de MaaT Pharma, était l’invité Laure Closier dans la rubrique #FrenchTech de Good Morning Business.
👉 Revoir l’interview ici : www.bfmtv.com/economie/rep...
@bfmbusiness.bsky.social
👉 Revoir l’interview ici : www.bfmtv.com/economie/rep...
@bfmbusiness.bsky.social
📰 MaaT Pharma featured in Drug Discovery World for promising preclinical results of our anti-tumor microbiotherapy MaaT034! This is an important milestone in our mission to transform cancer treatment with microbiome-based therapies.
👉 Read the full article here: www.ddw-online.com/maat-pharma-...
👉 Read the full article here: www.ddw-online.com/maat-pharma-...
MaaT Pharma releases positive results for anti-tumour candidate - Drug Discovery World (DDW)
Biotechnology company MaaT Pharma has announced preclinical results for its drug candidate MaaT034, including promising anti-tumour efficacy results and immune activation.
www.ddw-online.com
November 19, 2025 at 11:22 AM
📰 MaaT Pharma featured in Drug Discovery World for promising preclinical results of our anti-tumor microbiotherapy MaaT034! This is an important milestone in our mission to transform cancer treatment with microbiome-based therapies.
👉 Read the full article here: www.ddw-online.com/maat-pharma-...
👉 Read the full article here: www.ddw-online.com/maat-pharma-...
📅 Rencontrez le management de MaaT Pharma lors du Salon Investir Day le 25 novembre 2025, sur le stand L36 !
🦠 Eric Soyer prendra la parole lors d’une intervention sur le thème « Construire un leader du microbiote : la stratégie de MaaT Pharma ».
📍 Carrousel du Louvre, 99 rue de Rivoli, 75001 Paris
🦠 Eric Soyer prendra la parole lors d’une intervention sur le thème « Construire un leader du microbiote : la stratégie de MaaT Pharma ».
📍 Carrousel du Louvre, 99 rue de Rivoli, 75001 Paris
November 18, 2025 at 11:18 AM
📅 Rencontrez le management de MaaT Pharma lors du Salon Investir Day le 25 novembre 2025, sur le stand L36 !
🦠 Eric Soyer prendra la parole lors d’une intervention sur le thème « Construire un leader du microbiote : la stratégie de MaaT Pharma ».
📍 Carrousel du Louvre, 99 rue de Rivoli, 75001 Paris
🦠 Eric Soyer prendra la parole lors d’une intervention sur le thème « Construire un leader du microbiote : la stratégie de MaaT Pharma ».
📍 Carrousel du Louvre, 99 rue de Rivoli, 75001 Paris
📅 Fiers de participer au 24ème congrès annuel de la SFGM-TC 2025, à Genève !
🔬 Nous présenterons à nouveau des données cliniques issues du programme EAP sous la forme d’une communication orale, ainsi que deux posters dédiés à MaaT013 et MaaT033.
🔎 Toutes les informations dans le visuel ci-dessous 👇
🔬 Nous présenterons à nouveau des données cliniques issues du programme EAP sous la forme d’une communication orale, ainsi que deux posters dédiés à MaaT013 et MaaT033.
🔎 Toutes les informations dans le visuel ci-dessous 👇
November 17, 2025 at 11:20 AM
📅 Fiers de participer au 24ème congrès annuel de la SFGM-TC 2025, à Genève !
🔬 Nous présenterons à nouveau des données cliniques issues du programme EAP sous la forme d’une communication orale, ainsi que deux posters dédiés à MaaT013 et MaaT033.
🔎 Toutes les informations dans le visuel ci-dessous 👇
🔬 Nous présenterons à nouveau des données cliniques issues du programme EAP sous la forme d’une communication orale, ainsi que deux posters dédiés à MaaT013 et MaaT033.
🔎 Toutes les informations dans le visuel ci-dessous 👇
📰 [#PressRelease] - MaaT Pharma announces the successful completion of its Global Offering of €9.1 million
👉 www.maatpharma.com/november-14-...
👉 www.maatpharma.com/november-14-...
November 14, 2025 at 10:29 PM
📰 [#PressRelease] - MaaT Pharma announces the successful completion of its Global Offering of €9.1 million
👉 www.maatpharma.com/november-14-...
👉 www.maatpharma.com/november-14-...
📰 [#PressRelease] – MaaT Pharma Launches a Capital Increase of Approximately €9 Million
👉 Read the press release: www.maatpharma.com/november-13-...
👉 Read the press release: www.maatpharma.com/november-13-...
November 13, 2025 at 8:36 PM
📰 [#PressRelease] – MaaT Pharma Launches a Capital Increase of Approximately €9 Million
👉 Read the press release: www.maatpharma.com/november-13-...
👉 Read the press release: www.maatpharma.com/november-13-...
📰 MaaT Pharma To Present Updated Preclinical Data at SITC (@sitcancer.bsky.social) 2025.
We’re excited to share promising updated results for MaaT034 showing immune activation and anti-tumor activity in germ-free models.
👉 Full press release: www.maatpharma.com/november-5-2...
We’re excited to share promising updated results for MaaT034 showing immune activation and anti-tumor activity in germ-free models.
👉 Full press release: www.maatpharma.com/november-5-2...
November 5, 2025 at 6:45 AM
📰 MaaT Pharma To Present Updated Preclinical Data at SITC (@sitcancer.bsky.social) 2025.
We’re excited to share promising updated results for MaaT034 showing immune activation and anti-tumor activity in germ-free models.
👉 Full press release: www.maatpharma.com/november-5-2...
We’re excited to share promising updated results for MaaT034 showing immune activation and anti-tumor activity in germ-free models.
👉 Full press release: www.maatpharma.com/november-5-2...
📰 [PressRelease] – We’re thrilled to announce that our Phase 3 results evaluating Xervyteg® (MaaT013) in acute Graft-versus-Host Disease (#aGvHD) have been selected for oral presentation at ASH Congress 2025.
👉 Read the full press release: www.maatpharma.com/november-3-2...
👉 Read the full press release: www.maatpharma.com/november-3-2...
November 5, 2025 at 5:09 AM
📰 [PressRelease] – We’re thrilled to announce that our Phase 3 results evaluating Xervyteg® (MaaT013) in acute Graft-versus-Host Disease (#aGvHD) have been selected for oral presentation at ASH Congress 2025.
👉 Read the full press release: www.maatpharma.com/november-3-2...
👉 Read the full press release: www.maatpharma.com/november-3-2...
📄 [#PressRelease] - MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update
📍Next stops: SITC, SFGM-TC, Investir Day, ASH – see you there!
👉 Read the full press release: www.maatpharma.com/november-4-2...
📍Next stops: SITC, SFGM-TC, Investir Day, ASH – see you there!
👉 Read the full press release: www.maatpharma.com/november-4-2...
November 4, 2025 at 6:53 AM
📄 [#PressRelease] - MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update
📍Next stops: SITC, SFGM-TC, Investir Day, ASH – see you there!
👉 Read the full press release: www.maatpharma.com/november-4-2...
📍Next stops: SITC, SFGM-TC, Investir Day, ASH – see you there!
👉 Read the full press release: www.maatpharma.com/november-4-2...
📢 Proud to see our lead candidate MaaT013 highlighted in a new review in Current Opinion in Immunology by E. Godefroy and F. Altare, exploring how the gut microbiota regulates immune responses in acute graft-versus-host disease (#aGvHD).
🔬Open-access article: www.sciencedirect.com/science/arti...
🔬Open-access article: www.sciencedirect.com/science/arti...
October 30, 2025 at 11:28 AM
📢 Proud to see our lead candidate MaaT013 highlighted in a new review in Current Opinion in Immunology by E. Godefroy and F. Altare, exploring how the gut microbiota regulates immune responses in acute graft-versus-host disease (#aGvHD).
🔬Open-access article: www.sciencedirect.com/science/arti...
🔬Open-access article: www.sciencedirect.com/science/arti...
📢 Meet Sheri Simmons, Acting Chief Scientific Officer at MaaT Pharma, during the Annual Meeting of the SITC in National Harbor, Maryland, USA.
🔬 On Friday, November 7, Sheri will present our preclinical findings on MaaT034, our next generation co-cultured microbiome ecosystem therapy candidate.
🔬 On Friday, November 7, Sheri will present our preclinical findings on MaaT034, our next generation co-cultured microbiome ecosystem therapy candidate.
October 28, 2025 at 11:02 AM
📢 Meet Sheri Simmons, Acting Chief Scientific Officer at MaaT Pharma, during the Annual Meeting of the SITC in National Harbor, Maryland, USA.
🔬 On Friday, November 7, Sheri will present our preclinical findings on MaaT034, our next generation co-cultured microbiome ecosystem therapy candidate.
🔬 On Friday, November 7, Sheri will present our preclinical findings on MaaT034, our next generation co-cultured microbiome ecosystem therapy candidate.
Proud to share that MaaT013 (Xervyteg®) clinical data were featured in the latest special issue on acute Graft-versus-Host Disease (#aGvHD) in Current Opinion in Immunology.
🔗Open-access article here: sciencedirect.com/science/arti...
#AlloHCT #Hematology
🔗Open-access article here: sciencedirect.com/science/arti...
#AlloHCT #Hematology
Emerging novel therapies for steroid-refractory acute graft-versus-host disease: recent advances and future directions
Acute graft-versus-host disease (aGVHD) is a significant complication of allogeneic hematopoietic cell transplantation (allo-HCT), characterized by im…
sciencedirect.com
October 23, 2025 at 12:23 PM
Proud to share that MaaT013 (Xervyteg®) clinical data were featured in the latest special issue on acute Graft-versus-Host Disease (#aGvHD) in Current Opinion in Immunology.
🔗Open-access article here: sciencedirect.com/science/arti...
#AlloHCT #Hematology
🔗Open-access article here: sciencedirect.com/science/arti...
#AlloHCT #Hematology
📢 Join MaaT Pharma as an 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝗶𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗜𝗻𝘁𝗲𝗿𝗻 (𝗠/𝗙)!
📩 Interested? Send your CV and a short motivation email to careers@maat-pharma.com to apply now!
🔬 Full job description: www.maatpharma.com/wp-content/u...
🎓 6-month internship – starting early 2026
📍 Saint-Quentin-Fallavier (France)
📩 Interested? Send your CV and a short motivation email to careers@maat-pharma.com to apply now!
🔬 Full job description: www.maatpharma.com/wp-content/u...
🎓 6-month internship – starting early 2026
📍 Saint-Quentin-Fallavier (France)
October 20, 2025 at 2:30 PM
📢 Join MaaT Pharma as an 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝗶𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗜𝗻𝘁𝗲𝗿𝗻 (𝗠/𝗙)!
📩 Interested? Send your CV and a short motivation email to careers@maat-pharma.com to apply now!
🔬 Full job description: www.maatpharma.com/wp-content/u...
🎓 6-month internship – starting early 2026
📍 Saint-Quentin-Fallavier (France)
📩 Interested? Send your CV and a short motivation email to careers@maat-pharma.com to apply now!
🔬 Full job description: www.maatpharma.com/wp-content/u...
🎓 6-month internship – starting early 2026
📍 Saint-Quentin-Fallavier (France)